Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis (2015)
Journal Article
Brooks, S. E., Bonney, S. A., Lee, C., Publicover, A., Khan, G., Smits, E. L., Sigurdardottir, D., Arno, M., Li, D., Mills, K. I., Pulford, K., Banham, A. H., Van Tendeloo, V., Mufti, G. J., Rammensee, H. G., Elliott, T. J., Orchard, K. H., & Guinn, B. A. (2015). Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. PLoS ONE, 10(10), Article e0140483. https://doi.org/10.1371/journal.pone.0140483

Immunotherapy treatments for cancer are becoming increasingly successful, however to further improve our understanding of the T-cell recognition involved in effective responses and to encourage moves towards the development of personalised treatments... Read More about Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis.

Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer (2015)
Journal Article
Khan, G., Brooks, S. E., Mills, K. I., & Guinn, B.-A. (2015). Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer. Biomarkers in Cancer, 7, 31–38. https://doi.org/10.4137/bic.s28378

Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Ther... Read More about Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer.